Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alexion's Kanuma Fails To Impress NICE

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, says it is not recommending Alexion's Kanuma (sebelipase alfa) for one set of patients with lysosomal acid lipase deficiency, but wants more evidence when considering another group of patients with the same rare genetic disorder. The institute is concerned that the drug is not good value for the National Health Service, while Alexion says NICE has failed to recognize the Kanuma's "transformative innovation."

Advertisement
Advertisement
UsernamePublicRestriction

Register

SC064531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel